Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Estrogen Receptor-positive”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Not applicableStudy completedNCT06006910
What this trial is testing

Electronic Medical Record-Based Nudge to Reduce SLNB

Who this might be right for
Breast CancerEstrogen-receptor-positive Breast Cancer
University of Pittsburgh Medical Center 7
Large-scale testing (Phase 3)Active Not RecruitingNCT01953588
What this trial is testing

Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery

Who this might be right for
Estrogen Receptor-positive Breast CancerHER2-negative Breast CancerInvasive Ductal Breast Carcinoma+6 more
Alliance for Clinical Trials in Oncology 1,473
Large-scale testing (Phase 3)Not Yet RecruitingNCT07827573
What this trial is testing

Learn How Well Participants With a Specific Type of Early Breast Cancer (ER-Positive, HER2-Negative) Tolerate and Stay on Treatment With Giredestrant and How They Feel During Treatment

Who this might be right for
Early Breast CancerEstrogen Receptor-Positive Breast CancerHER2-Negative Breast Cancer
Hoffmann-La Roche 1,500
Testing effectiveness (Phase 2)Looking for participantsNCT06335069
What this trial is testing

18F-FDG Versus 68Ga-FAPI-46 as PET Tracer in ER-positive Breast Cancer.

Who this might be right for
Breast CancerBreast NeoplasmsBreast Diseases
Maastricht University Medical Center 20
Testing effectiveness (Phase 2)Ended earlyNCT02236572
What this trial is testing

Neoadj ph 2 AI Plus Everolimus in Postmenopausal Women w/ ER Pos/HER2 Neg, Low Risk Score

Who this might be right for
Breast Cancer
Yale University 17
Testing effectiveness (Phase 2)WithdrawnNCT03841747
What this trial is testing

Paclitaxel Plus Pembrolizumab vs. Paclitaxel Weekly in ER+ Luminal B Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Queen Mary University of London
Not applicableActive Not RecruitingNCT03503799
What this trial is testing

Reaching for Evidence-baSed Chemotherapy Use in Endocrine Sensitive Breast Cancer

Who this might be right for
Primary Invasive Breast CancerEstrogen Receptor Positive TumorHuman Epidermal Growth Factor Receptor 2 Negative Tumor
North Eastern German Society of Gynaecological Oncology 1,191
Large-scale testing (Phase 3)Looking for participantsNCT06195709
What this trial is testing

ECLECTIC: EstroTEP and Circulating Biomarkers for ER-positive HER2-negative Metastatic Breast Cancer Patients

Who this might be right for
Breast Carcinoma
Institut Curie 300
Testing effectiveness (Phase 2)Active Not RecruitingNCT04568616
What this trial is testing

Phase II Study of Neoadjuvant ArOMatase Inhibitor Therapy for ER+ Breast Cancer (NAOMI)

Who this might be right for
Breast CancerER Positive Breast Cancer
Dartmouth-Hitchcock Medical Center 178
Testing effectiveness (Phase 2)Looking for participantsNCT07100106
What this trial is testing

Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer

Who this might be right for
Breast Cancer
Genentech, Inc. 285
Testing effectiveness (Phase 2)WithdrawnNCT04901299
What this trial is testing

Fulvestrant + Neratinib In Breast Cancer

Who this might be right for
Stage IV (Metastatic) Breast CancerMetastatic Breast CancerER Positive Breast Cancer+3 more
Massachusetts General Hospital
Early research (Phase 1)Active Not RecruitingNCT03616587
What this trial is testing

Study of AZD9833 Alone or in Combination in Women With Advanced Breast Cancer.

Who this might be right for
ER+ HER2- Advanced Breast Cancer
AstraZeneca 396
Not applicableUnknownNCT00897065
What this trial is testing

Biomarkers in Predicting Response to Tamoxifen and Letrozole in Postmenopausal Women With Primary Breast Cancer Treated on Clinical Trial CAN-NCIC-MA17

Who this might be right for
Breast Cancer
Massachusetts General Hospital 957
Testing effectiveness (Phase 2)Study completedNCT02049957
What this trial is testing

Safety and Efficacy Study of Sapanisertib in Combination With Exemestane or Fulvestrant in Postmenopausal Women With Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Calithera Biosciences, Inc 118
Large-scale testing (Phase 3)WithdrawnNCT03658213
What this trial is testing

To Compare ZOLADEX 10.8 mg With ZOLADEX 3.6mg in Chinese Pre-menopausal ER+ HER2- Early Breast Cancer.

Who this might be right for
Breast Cancer
AstraZeneca
Testing effectiveness (Phase 2)Active Not RecruitingNCT03285412
What this trial is testing

CDK 4/6 Inhibitor, Ribociclib, With Adjuvant Endocrine Therapy for ER-positive Breast Cancer

Who this might be right for
Breast Cancer
Massachusetts General Hospital 120
Not applicableStudy completedNCT02186470
What this trial is testing

Intensity Modulated Accelerated Partial Breast Irradiation Before Surgery in Treating Older Patients With Hormone Responsive Stage 0-I Breast Cancer

Who this might be right for
Estrogen Receptor-positive Breast CancerInvasive Ductal Breast CarcinomaInvasive Ductal Breast Carcinoma With Predominant Intraductal Component+7 more
Ohio State University Comprehensive Cancer Center 22
Testing effectiveness (Phase 2)Ended earlyNCT00206492
What this trial is testing

Trial of ZD1839 (Iressa) and Tamoxifen in Breast Cancer Patients

Who this might be right for
Breast Cancer
Baylor Breast Care Center 3
Not applicableActive Not RecruitingNCT07316439
What this trial is testing

Comparison Between ER Loss and Triple-Negative Breast Cancer Guided by 18F-FES PET/CT in Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Fudan University 197
Testing effectiveness (Phase 2)Ended earlyNCT00674557
What this trial is testing

Exemestane With or Without ATN-224 in Treating Postmenopausal Women With Recurrent or Advanced Breast Cancer

Who this might be right for
Breast Cancer
Cancer Research UK 111
Next Page